Patient and Public Involvement & Engagement
Patient & Public Involvement in Research
People whose have lives are affected by cancer can offer cancer researchers and clinicians a unique and valuable insight into the needs of patients and people affected by cancer - this is why Patient & Public Involvement (PPI) in cancer research is so important
OCTO is committed to engaging with members of the public throughout each of our trials. Being involved can include:
- Helping to decide where clinical trials are needed
- Input on how trials are designed and run
- Assisting researchers with grant applications to secure funding for new trials
- Reviewing documentation which will be provided to potential trial participants
- Sitting on steering or oversight groups for clinical trials
- Taking part in training events for trial staff or future PPI representatives
- Helping to communicate the results and findings from completed trials
- Helping to publicise ongoing trials
OCTO is part of Oxford Cancer and so we work with the Oxford Cancer Patient and Public Advisory Group to appoint PPI representatives to our trials - their input is valuable from conception to completion of the trial.
If you’d like to become involved with PPI on OCTO Trials, or in other capacities in Oxford Cancer research, please follow this link for further information: https://www.cancer.ox.ac.uk/support/PPI
- About Us
- Work With Us: Careers In Trial Management
- Work With Us: Information for Investigators and Commercial Organisations
- Information for Patients, their Families and Carers
- Patient and Public Involvement & Engagement (PPIE)
- Current Trials
- Trials in Set Up
- SCALOP-2: Systemic therapy and Chemoradiation in Advanced Localised Pancreatic cancer–2
- CHARIOT: M6620 plus standard treatment in oesophageal and other cancer
- CYTOFLOC: Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer
- FRONTIER: Fluciclovine (18F) imaging of breast cancer
- NuTide:301: Safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.
- IMAGO: A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI
- TARDOX: Targeted chemotherapy using focused ultrasound for liver tumours
- CAMELLIA: Anti-CD47 antibody terapy in relapsed/refractory Haematological Malignancies
- ATOM: Atovaquone as Tumour HypOxia Modifier
- 6MP: A Phase II Clinical Trial in Patients with BRCA Defective Tumours
- AspECT: A Phase III, Randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia
- BKM120: Palliative thoracic radiotherapy plus BKM120
- CHOP-OR: Study of CHOP with Ofatumumab in Patients with Richter's Syndrome
- NEOPANC-01 - Pre-operative, Window-of-opportunity Study to Assess Gene Expression in Patients With Resectable, Locally Advanced, or Metastatic Pancreatic Cancer
- COG : Gefitinib for oesophageal cancer progressing after chemotherapy
- DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring
- DEBIOC: Dual Erb B Inhibition in Oesophago-gastric Cancer
- DOC-MEK: A double-blind randomized phase 2 trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
- EnROL: Conventional versus laproscopic surgery for colorectal cancer within an enhanced programme
- FOXFIRE: An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer
- LINES: Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma
- MErCuRIC1: MEK and MET Inhibition in Colorectal Cance
- MPP: Application of mobile phone technology for managing chemotherapy-associated side-effects
- OXO-PCR-01: Oxford Ovarian Cancer Predict Chemotherapy Response 01
- PACMEL: A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
- PemBla: A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer
- ART: Anal squamous cell carcinoma: Investigation of functional imaging during chemoRadioTherapy
- RHYTHM-1: Modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer
- RADVAN: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases.
- SPARC: SBRT pre-operatively for pancreatic cancer
- VICTOR: Post-treatment stage of a Phase III, randomised, double blind, placebo-controlled study of rofecoxib (VIOXX®) in colorectal cancer patients following potentially curative therapy.
- WBRT: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised Phase III trial.
- QUASAR2: Multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer
- SONATINA: A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.
- SCOT: Short Course Oncology Treatment - A study of adjuvant chemotherapy in colorectal cancer by the CACTUS and OCTO groups.